Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Event Logistics

- PMLiVE

FDA approves Citius’ immunotherapy Lymphir to treat cutaneous T-cell lymphoma

The rare type of non-Hodgkin lymphoma currently affects about 40,000 people in the US

- PMLiVE

Pfizer and BioNTech share late-stage results for COVID-19/flu combination vaccine

The combined vaccine approach could simplify immunisation practices and lead to higher uptake

- PMLiVE

Mayo Clinic explores AI and brain waves for neurodegenerative disease diagnosis

The team is using AI to assist in analysing routine EEGs for early identification of brain disorders

- PMLiVE

UK study reveals previously unknown genetic causes of colorectal cancer

The third most commonly diagnosed cancer globally is responsible for more than 44,000 new cases in the UK every year

- PMLiVE

Pharma-exclusive Webinar: Virtual Publication Planning, Co-Development, & Reviews

Dive into Impetus Digital's exclusive webinar on Medical Publications to learn from experts about the latest in publication planning, co-development, and reviews, and enhance your strategies in the virtual realm.

Impetus Digital

Boosting Memory with Frequent Virtual Touchpoints – Perks of Virtual Medical Education

Unlock the secrets to effective learning with our latest video! Learn how frequent, short virtual sessions utilize the Recency Effect to improve memorization and avoid fatigue, outperforming long, one-time meetings....

Impetus Digital

- PMLiVE

Sanofi shares positive phase 3 results for Sarclisa in newly diagnosed multiple myeloma

More than 180,000 new cases of the haematological malignancy are diagnosed globally every year

- PMLiVE

NICE recommends Theramex’s Eladynos to treat bone disease after menopause

Osteoporosis, which particularly impacts older women after menopause, currently affects 3.8 million people in the UK

- PMLiVE

Innovative Trials partners with GOSH and Oliver Patch for childhood cancer research

Childhood cancers, including leukaemia and lymphoma, affect 400,000 children globally every year

- PMLiVE

FDA approves Servier’s Voranigo to treat brain cancer in adult and paediatric patients

The drug is now the first targeted treatment approved in the US for grade 2 IDH-mutant glioma

- PMLiVE

Sobi and Apellis’ pegcetacoplan shows promise in phase 3 rare kidney disease study

There are currently no treatments that target the underlying cause of C3G or IC-MPGN

- PMLiVE

UCLA launches study of personalised cancer vaccine in paediatric brain tumours

H3 G34-mutant diffuse hemispheric gliomas are brain tumours commonly found in adolescents and young adults

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links